On behalf of the Board of Directors, I would like to provide a New Year update following the recent strategic developments, including the divestment of CannGros ApS to StenoCare A/S and the forthcoming delisting of DanCann Pharma A/S.

Following completion of the delisting process, the Company’s remaining asset base will consist of three core elements:

- A residual shareholding in StenoCare A/S 

- Cash and cash equivalents 

- BP1 – the Company’s GMP-certified production facility 

During the transition period, a portion of the Company’s StenoCare shareholding has been realized to support ongoing operations and to meet outstanding obligations to a limited number of minor creditors. In parallel, DanCann Pharma A/S continues to act as a service provider to StenoCare A/S for the remainder of Q1 2026, after which StenoCare is expected to internalize these activities.

Looking ahead, the Company’s strategic optionality is primarily contingent upon the successful divestment of BP1. Historically, the production facility has on several occasions been close to completion of a transaction, and management continues to engage in constructive dialogue with multiple interested parties regarding a potential sale.

Until clarity is achieved on the outcome of the BP1 process, it would be premature to provide definitive guidance on the Company’s future strategy or capital structure. The Board remains focused on safeguarding shareholder value and ensuring that all strategic alternatives are assessed with appropriate diligence and financial discipline.

Further communication will be provided as material developments occur.

Yours sincerely,

Carsten Trads 

Chairman of the Board 

DanCann Pharma A/S

Further information

For further information regarding the delisting, please contact:

Carsten Trads, Chairman

E-mail: ctr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, please visit: www.dancann.com.

Forward-looking statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company''s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company''s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company''s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company''s public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.